ir.blueprintmedicines.com/news-releases/…

This is the flooring in the dentist's office and I am thinking where's the ladder?

Electroflooresis!

Here's FierceBiotech @AGKootenay story on client Blueprint Medicines $BPMC #AACR22 data on potential treatment for certain types/forms of lung cancer: fiercebiotech.com/biotech/aacr-b…

My dad was just diagnosed in April with stage 4 Lung Cancer. May is Lung Cancer Hope month. Please help give patients hope by supporting research and support at LUNGevity: lungevity.donordrive.com/participant/Br…

$BPMC Blueprint Medicines Announces Positive Top-line Results from PIONEER Trial of AYVAKIT® (avapritinib) in Patients with Non-Advanced Systemic Mastocytosis Achieving Primary and All Key Secondary Endpoints webchronicletoday.com/blueprint-medi…

PACC EGFR mt is a heterogenous population in NSCLC. Structure and function classification guides tx selections and development. #TTLC23 Xiuning Le MD PhD #LCSM IASLC

Lots of hope for those with #C797S resistance mechanisms to #osimertinib. Look at all these compounds in development! Julia Rotow MD EGFR Resisters #lcsm #EGFR #lungcancer #TTLC23

Unanswered questions and future directions in #EGFR #Exon20insertions #lcsm #EGFR #lungcancer Zosia Piotrowska #TTLC23 EGFR Resisters Exon 20 Group, a multistakeholder organization

Joshua Sabari, MD at #TTLC23: if you don’t test for #METex14 you won’t find it! Don’t skip #METex14 skipping mutation! IASLC #lcsm

Honored to discuss "rare EGFR mutations" at #TTLC23 with friends and colleagues. EGFR Resisters Exon 20 Group, a multistakeholder organization. Trials are ongoing for PACC mutations!

$BPMC FDA Approves AYVAKIT as the First and Only Treatment for Indolent Systemic Mastocytosis prnewswire.com/news-releases/…

This exciting publication on RLY-4008 is officially live in AACR Cancer Discovery Journal. Special thanks to our incredible team of Relayers, Vivek Subbiah of MD Anderson Cancer Center & our collaborators and investigators for their relentless dedication to the advancement of this

aacrjournals.org/cancerdiscover…

50% of patients after progression on PIK3CA inhibitors acquire secondary genomic alterations within the PI3K-pathway. All mutations overcome by novel patient allosteric PIK3CA inhibitor RLY2608. Great work ⁦AndreasVarkaris⁩! aacrjournals.org/cancerdiscover…

Our first publication on RLY-2608, an investigational, first known isoform and mutant-selective allosteric PI3Kα inhibitor, is officially live in Cancer Discovery. We extend our most sincere gratitude to our remarkable team of Relayers, collaborators, investigators and patients who are

Thrilled to announce the launch of our new patient advocacy organization PIK3CA Path Breakers ers! We are excited about partnering with pts, advocates, oncologists, biotech, pharma, and others to improve care for pts with PIK3CA altered breast cancer.

I would say it’s a mute point since alpelisib use will decline significantly due to capivasertib. I would be interested to hear more about the “programming error” and which program was used so that we can learn from it for future trials.

Cancers should no longer be classified only by their organ of origin - it's time for molecular characteristics to be used to classify tumors; for clinical practice as well as regulatory decision making. Commentary nature h/t Eric Topol

Today, we announced a clinical trial collaboration to develop RLY-2608 with atirmociclib, Pfizer’s next-generation selective CDK4 inhibitor currently in Phase 1 studies, in triplet combination in patients with PI3Kα-mutated, HR+, HER2-metastatic #breastcancer. Clinical start by